Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Enzalutamide
Related studies linked through entity extraction aliases.
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE3
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
- Status
- RECRUITING
- Phase
- PHASE2
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)
- Status
- COMPLETED
- Phase
- PHASE2
a Vigibase Pharmacovigilance Study of ENzalutamide Drug-induced neurotoxicitY
- Status
- COMPLETED
- Phase
- N/A
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
- Status
- COMPLETED
- Phase
- PHASE1
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)
- Status
- TERMINATED
- Phase
- PHASE2
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE1/PHASE2
Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC
- Status
- TERMINATED
- Phase
- PHASE2
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
- Status
- UNKNOWN
- Phase
- PHASE2